By ITU Admin on 25/02/09 at 12:01 am
Atypical findings in anti-doping are an area of much concern and misunderstanding. The new World Anti-doping Agency (WADA) Code, effective January 1, 2009, has introduced the concept of atypical findings. The WADA magazine Play True (Issue 3-2008) explains that laboratories are directed to report the presence of a prohibited substance, which may also be produced endogenously, as an atypical finding, which is subject to further investigation. Upon receipt of an A sample atypical finding where a review by the anti-doping organization responsible for the results management does not reveal an applicable therapeutic use exemption or that a departure is the cause for the atypical finding, the anti-doping organization will conduct the required investigation. Upon completion of the investigation, the athlete and other anti-doping organizations (including WADA) will be notified whether or not the atypical finding will be brought forward as an adverse analytical finding.
If you have any questions regarding Anti-doping, please contact Leslie Buchanan, ITUs Anti-doping Director at firstname.lastname@example.org.